x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

BiotechTV - News

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

science life sciences

All Episodes

00:25:56

Protagonist Therapeutics has two medicines in front...

BiotechTV - News ·

2026/02/20

CEO Dinesh Patel and Chief Discovery Officer Ashok Bhandari walk us through the company's R&D expertise, and we discuss programs covering IL-23, IL-17, a hepcidin mimetic, and obesity medicines.

en-us

00:25:30

Cambridge, UK based Arecor uses formulation and...

BiotechTV - News ·

2026/02/19

CEO Sarah Howell discusses three key aspects of the business: helping with reformulation, its own proprietary insulin products, and developing oral peptides like GLPs.

en-us

00:11:24

NewLimit is using epigenetic reprogramming to bring...

BiotechTV - News ·

2026/02/19

Co-Founder & President Jacob Kimmel describes the science behind how this works, and the enormous amount of work that goes into choosing which transcription factors to target. The company is currently in IND enabling studies.

en-us

00:10:14

Gordian Biotechnology announced that it will be using...

BiotechTV - News ·

2026/02/18

Co-Founder & CSO Martin Borch Jensen describes the deal and walks us through Gordian's process that enables it to do a multiplicity of in vivo screening in months that previously would have taken years.

en-us

00:11:45

Cambridge, UK based Microbiotica announced results...

BiotechTV - News ·

2026/02/18

CEO Tim Sharpington and CMO Robert Tansley walk us through the treatment, which contains a defined consortium of eight live gut commensal bacterial strains, and the data.

en-us

00:13:20

Ocular Therapeutix Chair & CEO Pravin Dugel discusses...

BiotechTV - News ·

2026/02/17

The study showed that AXPAXLI has superior maintenance of visual acuity at Week 36 vs EYLEA. Dr. Dugel discusses what he believes the significance of this is, and delves into durability data going out to 52 weeks.

en-us

00:15:35

Oxford based Infinitopes raised an additional $15.4M...

BiotechTV - News ·

2026/02/17

Co-Founder & CEO Jonathan Kwok describes the company's platform, which helps it identify highly expressed and immunogenic tumor antigens, and how the lead program for oesophageal cancer will have data by the end of 2026.

en-us

00:09:35

From Oxford: Carlo Rinaldi's team has received two...

BiotechTV - News ·

2026/02/17

He describes his work in these diseases and how Oxford-Harrington has provided funding and advice that has been valuable beyond the feedback he typically receives in an academic setting.

en-us

00:21:04

From Oxford: Professor Matthew Wood describes the...

BiotechTV - News ·

2026/02/17

He highlights the centre's Scholars program, which researchers anywhere can apply for and funds ten new drug development programs each year. Plus the centre's accelerator program and plans for a rare disease investment fund. He also discusses how regulatory changes at places like MHRA can help the rare disease community.

en-us

00:42:26

Biotech CEOs discuss the state of the industry, what...

BiotechTV - News ·

2026/02/13

MassBio President & CEO Kendalle Burlin O'Connell moderates a discussion with Aurora Therapeutics CEO Ed Kaye and DaCapo Brainscience CEO Leslie Williams about being biotech leaders during this volatile time for the industry. They stress that a key to success is that everyone in the industry work together towards shared goals.

en-us

00:18:55

Analyst Thursdays: Mizuho Senior Biotech Analyst...

BiotechTV - News ·

2026/02/12

He discusses upcoming readouts for IDEAYA Biosciences, Ocular Therapeutix (how it might affect EyePoint), and Palvella Therapeutics. Plus, his take on the recent Corvus atopic dermatitis data.

en-us

00:13:13

Upstream Bio's CEO Rand Sutherland discusses today's...

BiotechTV - News ·

2026/02/11

He describes top-line data the company saw across three different doses, next steps, and also shares an update on additional indications of chronic rhinosinusitis with nasal polyps and COPD it is being developed for.

en-us

00:27:18

Corvus Pharma CEO Richard Miller fields follow-up...

BiotechTV - News ·

2026/01/28

He discusses learnings about durability, dosing, biomarkers, and more for this first-in-class target.

en-us

00:16:46

Analysts Thursdays: Clear Street Senior Biotech...

BiotechTV - News ·

2026/01/22

She discusses Arrivent Biopharma, Oruka Therapeutics, Jade Biosciences, Zura Bio, and Pavella Therapeutics.

en-us

00:11:28

SF Healthcare Week: Perceptive Advisors' Joe Edelman,...

BiotechTV - News ·

2026/01/17

He talks about Perceptive's investment philosophy, his take on the year ahead, areas he thinks are over and under hyped, and thoughts on China. Plus, the rationale for a few of his top holdings.

en-us

00:11:55

SF Healthcare Week: Cytokinetics CEO Robert Blum...

BiotechTV - News ·

2026/01/16

He discussed the REMS, launch plans, market opportunity, payors, and the metrics that the company will offer publicly over time. Plus, previewing a key new data readout that will be coming in the second quarter of this year.

en-us

00:10:51

SF Healthcare Week: Sana Bio's CEO Steve Harr...

BiotechTV - News ·

2026/01/16

He describes one patient data from an investigator led study in Europe, and explains how Sana's program is slighly different. The company aims to file an IND this year. Plus, discussing the company's unique delivery mechanism for in vivo CAR-T.

en-us

00:13:04

SF Healthcare Week: Alumis' CEO Martin Babler walks...

BiotechTV - News ·

2026/01/15

He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.

en-us

00:10:04

SF Healthcare Week: CEO Heather Turner tells us about...

BiotechTV - News ·

2026/01/15

She walks us through LB-102, a methylated derivative of amisulpride, a therapy that has a history of success in Europe. Plus, her thoughts on the obesity market (she was CEO of Carmot Therapeutics at the time of its acquisition by Roche) and being a member of the Biotech CEO Sisterhood.

en-us

00:14:24

SF Healthcare Week: Neurocrine Biosciences CEO Kyle...

BiotechTV - News ·

2026/01/15

Plus, how the neuroscience company has used its long history working with corticotropin releasing factor to move into obesity, with a project that acts on targets in the brain.

en-us

376 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter